Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Extension “Wild Card” In Hatch/Lieberman Bill Depends On Five Factors

Executive Summary

Under a draft "BioShield II" bill from Sens. Orrin Hatch (R-Utah) and Joe Lieberman (D-Conn.), the length of a "wild card" patent extension would be partially dependent on the availability of alternatives to the bioterrorism countermeasure

You may also be interested in...



Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing

Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug

Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing

Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug

Hatch/Lieberman “BioShield II” Sets 180-Day Window For “Wild Card” Patents

Manufacturers who enter into biodefense contracts must notify the government within 180 days which patent would be covered by a potential "wild card" extension under the final version of "BioShield II" legislation from Sens. Orrin Hatch (R-Utah), Joe Lieberman (D-Conn.) and Sam Brownback (R-Kan.)

Related Content

Topics

UsernamePublicRestriction

Register

PS045613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel